The Official Website of the Long-Term Investor
Results 41 - 50 of 1709 : Previous 1 2 3 4 5 6 7 8 9 Next
Why Pfizer's Earnings Are Outstanding
All cash flow is not created equal.
Whoa! My Stock Just Crushed the Market!
These stocks just took off, but are they about to make a return trip to Earth?
GSK's Witty Pumps Up the Pharma's Drug Pipeline Prospects
GSK CEO Andrew Witty has been trying to plant seeds of optimism in an uncertain global financial market.
This Just In: More Upgrades and Downgrades
Geron gives up. So does Wall Street.
1 Reason Johnson & Johnson's Earnings Aren't So Hot
Don't just count the cash, time it.
Is GlaxoSmithKline Good Enough for You?
Keep your eye on margins.
The Only Way to Survive in This Drug Market
Gilead and J&J sign another pact.
Does Novartis Pass Buffett's Test?
Here's one of Buffett's favorite metrics for evaluating companies.
When Giving Up Is a Good Move in Biotech
Geron calls it quits with stem cells.
This Just In: Upgrades and Downgrades
A Swann song for Pfizer?
BATS data provided in real-time. NYSE, NASDAQ and AMEX data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates and Analyst Ratings provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK